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Abstract
Human trypanosomiasis is a neglected tropical disease caused by protozoan parasites of
the genus Trypanosoma. Trypanosoma brucei is responsible for sleeping sickness, also called
African trypanosomiasis, while Trypanosoma cruzi causes Chagas disease, or American
trypanosomiasis. Together, these diseases are responsible for significant mortality, mor-
bidity and lost productivity in the endemic regions. There are no vaccines and treatments
rely on drugs with limited efficacy, high cost, serious side effects and long administration
periods. Since these diseases affect mostly the poor, there is no economic interest in the
development of new drugs by pharmaceutical companies, and hopes for new treatments
rely on public initiatives, public-private partnerships or philanthropic programs. The first
step in the discovery of new drugs involves the identification of active molecules as
starting points for further development, by either employing whole cells or by specific
molecular target screenings. Research efforts undertaken by the authors’ groups have
focused on exploiting both strategies in the search for new molecules for trypanosomiasis
drug discovery. In this chapter, we focus on Chagas disease and the recently uncovered
potential of using sirtuins as targets for infection control.
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1. Introduction
Despite the efforts of many individuals and organizations over the years, human trypanosomi-
asis remains one of the most neglected diseases in the world. Chagas disease in particular, is a
leading cause of disease and disability in Latin America, with thousands of deaths every year [1].
The negligence is particularly patented by the lack of new drugs. Indeed, the available treatment
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options, benznidazole and nifurtimox (Figure 1), were discovered more than 40 years ago.
Different strategies have been employed to control the disease, but the most impactful so far
has been the control of the transmitting vector led by theWorld Health Organization (WHO) and
Pan American Health Organization (PAHO). Vector control has caused the reduction of cases
from a staggering 24 million in the 1980s to about 6 million nowadays [1, 2], with some countries
considered to be free of domestic vectorial transmission. Continued and rigorous implementa-
tion of the disinfestation programs in the remaining zones should decrease even further the
global numbers of Trypanosoma cruzi vectorial transmission. Also, the screening of donor blood
and transplant organs in endemic regions and other parts of the world has greatly reduced the
Figure 1. Various trypanocidal agents.
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number of cases transmitted by this route. Whereas the global interruption of the domestic cycle
will be a major breakthrough and reduce to a minimum the number of new cases of Chagas
disease, complete eradication of the parasite, however, is unlikely to be achieved due to the huge
natural reservoir of T. cruzi and the many species of triatomines capable of its transmission in the
sylvatic environment [3–5].
What then, stands in the way of disease control for Chagas? First, no major technological
advances are required to interrupt vectorial transmission responsible for the majority of new
cases; second, decades of research in the molecular understanding of T. cruzi biology, the partic-
ularities of pathogenesis of the disease or the dynamics of immune response against the parasite
have failed to translate into therapeutic alternatives; and finally, vaccination, either preventive or
therapeutic, has remained an elusive achievement. The answer lies in new therapeutics. New,
safer, cheap, easy to administer and efficacious drugs that are able to treat not only new cases,
but also the millions of people already affected by the chronic stage and indeterminate form of
the disease. There is growing evidence that chronic manifestations are ultimately related with
inflammation resulting from parasite persistence [6, 7] and effective treatment of these cases
would be highly beneficial to stop the development of symptomatology.
Active drug discovery efforts for Chagas disease have been restricted, until some years ago, to
just a very limited number of groups, mostly based in academia. As a consequence, results
have been sporadic, slow, ineffective and highly dependent upon intermittent funding, failing
to deliver an alternative treatment. Chagas disease is as much neglected by the pharmaceutical
industry as it is by research funding organizations, whose majority of funds are directed to
developed world diseases.
Only recently has drug discovery for Chagas been met with concerted, focused efforts. While
still not privately embraced by pharmaceutical companies, public-private partnerships have
been set up with the objective of bringing together the biology expertise from academia and
the technical expertise, facilities and resources from pharmaceutical industries. One organiza-
tion that is leading the efforts to find new therapies for neglected diseases, including human
trypanosomiasis, is the Drugs for Neglected Diseases Initiative (DNDi), that has been involved
in coordinating activities from early drug discovery to the launch and conclusion of clinical
trials for some candidates like inhibitors of ergosterol biosynthesis of T. cruzi. The Bill and
Melinda Gates Foundation, a non-governmental organization devoted to human development
in underdeveloped countries, has committed to help control neglected diseases by signing The
London Declaration on Neglected Diseases together with the WHO, the World Bank and 13
leading pharmaceutical industries. The Declaration states that by 2020 the signers will achieve,
among other ambitious milestones, the eradication of Human African trypanosomiasis (HAT)
and the control of American trypanosomiasis. Since then, other initiatives have been launched
with the objective of boosting the research in new drugs for Trypanosomal diseases, like the
European Commission Seventh Framework Program (FP7) consortia NMTrypI and KINDReD.
The recent award of the Nobel Prize in Physiology or Medicine 2015 to William C. Campbell,
Satoshi Omura and Youyou Tu is a recognition of the importance of drug discovery for
parasitology and should further increase the awareness of neglected diseases by the interna-
tional community.
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Pharmaceutical research and drug discovery for infectious disease have historically began with
what would be classified today as phenotypic assays, and can be traced to the pioneering work
of Paul Ehrlich in the nineteenth century, while testing the effect of different dyes in trypano-
somes [8]. Cultures of the microorganism of interest, bacteria or parasites, were incubated with a
compound of interest, and the selective staining of the dyes was monitored by microscopy.
Products of such “dye therapy” approaches were in the origin of well-known chemicals like the
crystal violet dye that was proposed to be used in blood banks of endemic areas to kill T. cruzi
parasites present in transfusion blood as a way to reduce transmission by this route [9]. Another
example is trypan blue, that is still widely used as a cell biology reagent and that was the starting
point for the design of the colorless analogue Suramin, a drug still in use today for the treatment
of HAT and infected animals as well [10]. Such early whole cells drug screening principles were
also central to the development of nifurtimox and benznidazole (Figure 1) in the 1960s and
1970s, by the pharmaceutical companies Bayer and Roche, respectively [11].
With the genomic era there was a dramatic shift in the way new drugs are discovered. The past
20 years have witnessed incredible advancements in genomics, proteomics, structural biology,
computational chemistry and structure based drug-design, that coupled with high-throughput
screening and combinatorial chemistry have helped to shape the reductionist mentality “one
gene—one protein—one drug” [12]. However, the complexity of many diseases and the capac-
ity of adaptation to adverse conditions, like the presence of a xenobiotic, evidenced by many
living cells, have brought the more naïve phenotypic whole-cell screening strategies back to
the spotlight. With modern phenotypic approaches, the effect of a pure molecule in a fully
intact whole living organism, bacteria, parasites or human-derived cell lines, results in the
identification of hit compounds that are potentially useful as scaffolds for further medicinal
chemistry optimization.
While early phenotypic screenings for T. cruzi sometimes used the insect-specific epimastigote
stage due of its extracellular nature and ease to culture, the use of reporter genes expressed
during the clinically relevant stage of the disease, the intracellular amastigotes, has met a
widespread application. The first of such assays was based upon the β-galactosidase-expres-
sing parasites that made possible the detection of anti-T. cruzi activity by a colorimetric
reaction [13]. Later, tdt-tomato and luciferase genes were also constitutively expressed in
parasites, allowing more sensitive measurement of a fluorescent or luminescent signals,
respectively [14].
However, the use of genetically unmodified parasites has always been an attractive pursuit,
made available only recently due to technologic advancements. Such cell-based assays were
developed by researchers at Institut Pasteur Korea and have met widespread use [15–18]. This
assay employed the use of wild type parasites of T. cruzi infecting a non-modified cell line and
the imaging of the resulting infection (in the amastigote stage) by high-content analysis (HCA)
microscopy. Furthermore, the assay was developed in the 384-well format, allowing a high
throughput testing of compounds. Preliminary cell toxicity is concomitantly determined by
quantifying the ratio of host cell nuclei, a clear advantage since it reduces the need of an
independent assay to assess this parameter. Using this screening assay, the authors of this
chapter have also screened a library of 4000 kinase/phosphatase-like inhibitors that allowed
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the identification of 11 compounds with strong anti-parasitic activity and selectivity, suitable
for follow up hit-to-lead optimization (unpublished results). In addition, a complementary
assay developed for phenotypic profiling also allowed the identification of several compounds
that interfered with the development and intracellular differentiation of T. cruzi. Compounds
that hindered the differentiation from trypomastigotes to amastigote and the replication of
amastigotes inside host cells are among the examples of “phenotypic” hits discovered (unpub-
lished results). Due to the complex genetics and still many unknown aspects of T. cruzi biology,
these types of compounds have the potential to constitute important chemical genomic tools
that may help answering fundamental questions like: what triggers stage differentiation and
what are the pathways involved? What factors are responsible for parasite persistence? How
are amastigotes kept dormant for years to decades in host cells, hidden from the immune
system? Due to the nature of the chemical library, it is likely that the compounds target kinases,
of which the T. cruzi genome has 190 annotated potential members [19]. T. cruzi and other
Trypanosomatids have a relatively big kinome when compared with other parasites that
undergo several stage differentiations and contact with distinct environments, like Plasmodium
spp. [20, 21]. One hypothesis is that while in metazoa and yeast the ultimate targets of many
signaling cascades are transcription factors, which then trigger the expression of new sets of
genes, Trypanosomatids have constitutive transcription of a majority of genes in large polycis-
tronic units, hinting at a greater role of post-translational modifications (PTMs) like phosphor-
ylation and acetylation.
2. Sirtuins: family and functions
Post-Translational Modifications (PTMs) represent one of the major mechanisms in regulating
protein function in all life forms. Through phosphorylation, acetylation, methylation, glycosyl-
ation and ubiquitination, cells greatly extend the possibilities beyond the coding genome [22].
PTMs can change the enzymatic activity of a protein, change its subcellular localization,
interfere with protein complexes assembly, increase or decrease its stability and induce inter-
actions with DNA and RNA [22, 23].
Discovered half a century ago and largely ignored for the following years, lysine acetylation
has re-emerged in the last two decades as a highly important PTM [24, 25]. Initial studies had
focused in the role of lysine acetylation in the regulation of chromatin structure and gene
expression, but with the advances in proteomic approaches, it was possible to begin to explore
the function of lysine acetylation in non-histone proteins [24, 25].
Studies based on proteomic analysis to describe the lysine-acetylated proteins repertoire of an
organism, called acetylome, have shown the presence of lysine acetylation in proteins from
different cellular compartments and involved in different biological processes in several organ-
isms [26]. Because of that, lysine acetylation has been placed by some authors in the same level
of biological relevance as phosphorylation [24, 25]. In fact, studies of the acetylome of mam-
malian cells revealed acetylation sites in 1750 different proteins [27], a number close to the
about 2000 proteins found to be phosphorylated [28].
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The “acetyl code” is maintained by three different protein types: the “writers”, lysine acetyltran-
sferases (KATs) that add acetyl groups to proteins, the “erasers”, lysine deacetylase (KDACs)
that remove acetyl groups, and “readers”, proteins that specifically recognize and bind acetyl-
lysine groups [26].
KDACs in particular have been the focus of great interest by the scientific community due to
their many roles in cell function and disease. KDACs are interchangeably called histone
deacetylases (HDACs), because the first discovered reactions catalyzed by these proteins were
the removal of acetyl groups in histone tails [24, 29].
HDACs are separated into four different classes based upon sequence homology (class I, II, III
and IV) and two different families: the histone deacetylase family and the sirtuin family, the
latter being all class III HDACs. While the first family has a limited set of molecular targets,
mainly composed of histones, sirtuins have a variety of substrates ranging from metabolic
enzymes to structural proteins, as well as histones [30–32]. The sirtuin family seems to be
ubiquitous throughout all kingdoms of life. The number of genes coding for sirtuins within
an organism ranges from as little as one in bacteria, to seven in vertebrates [33]. The sirtuin
family is further classified in 5 subclasses (I, II, III, IV and V) [34].
The most common reaction catalyzed by sirtuins is deacetylation. This reaction is of upmost
biological importance as there is a clear relation between the acetylation status of several
proteins and their cellular functions [35–38]. The deacetylase reaction requires (nicotinamide
adenine dinucleotide) NAD+, an acetylated lysine residue and produces deacetylated lysine,
nicotinamide and 20-O-acetyl-ADP-ribose (OAADPR) [39]. Studies on the kinetics and bio-
chemical properties of the enzymes revealed binding to the acetyl-lysine substrate prior to
NAD+. This is followed by nicotinamide cleavage fromNAD+, that is the first product released,
followed by deacetylated lysine and OAADPR [40] (Figure 2A). All sirtuins are strictly NAD+
dependent, a distinct characteristic that distinguishes them from other deacetylases. In fact,
SIRT6 is a sirtuin capable of tightly binding to NAD+ without the requirement of an acetylated
substrate, indicating that it may function as a NAD+ sensor [41].
Besides being an endogenous product of the deacetylation reaction, nicotinamide is also a
well-known inhibitor of sirtuins. Nicotinamide is an amide of nicotinic acid (vitamin B3) and
is part of common enzyme co-factors like NAD+ and NADP (nicotinamide adenine dinucleo-
tide phosphate) [42]. Intracellular physiological levels of nicotinamide in some mammalian
cells seem to be in the range similar to the IC50’s of some sirtuins reinforcing the hypothesis
that some sirtuins may act as NAD+ and nicotinamide sensors [43, 44].
OAADPR is another product of the deacetylation reaction [45] (Figure 2A). Early studies
characterizing this molecule found that quantitative microinjection into starfish oocytes led to
a blockage of oocyte maturation, indicating for the first time that OAADPR can evoke a
biological activity [46]. There is now mounting evidence that OAADPR can elicit downstream
responses that might synergize or antagonize the biological functions of sirtuin genes. So far,
OAADPR has demonstrated to be related with functions in gene silencing, ion channel modu-
lation and cell redox state maintenance [45].
Another reaction catalyzed by sirtuins is ADP-ribosylation. Although sirtuins were firstly
described as ADP-ribosyltransferases (Figure 2B), their deacetylase activity has quickly
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overshadowed this activity, and as a consequence the biological processes associated to this
reaction remains poorly understood [47]. In truth, sirtuins may have just deacetylase activity,
both, or be mostly ADP-ribosyltransferases. An example is SIRT4 that is an efficient in vitro
ADP-ribosyltransferase of histones that only recently was discovered to possess deacetylase
activity [48, 49]. There is an active debate on whether ADP-ribosylation is in fact a biologically
relevant function of sirtuins, or just an irrelevant side reaction/non-enzymatic artifact [50].
Nevertheless, some of the players in the dynamics of intracellular ADP-ribosylation have only
been recently identified and it is becoming apparent that this PTM might be relevant for the
modulation of important cell processes and signaling pathways like signal transduction mech-
anisms, transcription and DNA repair [51]. The ADP-ribose hydrolysis in Trypanosomatids
Figure 2. Sirtuin deacetylation and ADP-ribosylation mechanisms. (A) Sirtuins carry out protein deacetylation by remov-
ing acyl chains from protein lysine residues. This activity requires the cofactor nicotinamide adenine dinucleotide
(NAD+), such that nicotinamide is released with concomitant production of O-acetyl-ADP-ribose (O-AADPR). There is a
sirtuin-independent equilibrium between 20 and 30-O-AADPR isomers. The unspecified stereochemistry at the Cl0 position
of O-AADPR reflects the fast epimerization observed in solution between α and β-anomers. (B) A number of sirtuins also
exhibit ADP-ribosylating functionality. This reaction is also NAD+-dependent, as the cofactor acts as the source of ADP-
ribose. ‘X’ represents the nucleophilic side-chain of a protein residue.
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has recently been studied in both Trypanosoma brucei and Trypanosoma cruzi and found to be
mediated by a macrodomain with a conserved catalytic site [52].
Although (de)acetylation is the most common PTM, (de)acylation of other groups can be
targeted, like succinyl and malonyl groups. SIRT5 and SIRT6 are some examples of proteins
that perform deacylations of lysines other than acetyl groups, and their activities are important
regulators of cell functions [53–55].
There is a wealth of information regarding the structural features of sirtuins. To date, some 83
structures of sirtuins are available in the protein databank, many of them co-crystalized with
natural ligands or inhibitors. Though the available structures range from bacterial to mamma-
lian sirtuins, the majority of the structures originate from the human genome.
Although the sequence homology can vary significantly between sirtuins, especially between
prokaryotic and eukaryotic proteins, there is a conserved catalytic core of about 250 amino
acids common to all members in the family [56]. The structure similarity of the Plasmodium
falciparum PfSir2A with the mammalian SIRT5, despite a sequence homology of just 33% is a
clear illustration [56]. This core contains a Rossman fold domain that is a NAD+ binding site,
and a Zn2+ binding domain containing four highly conserved cysteine residues arranged in the
motif (CX2CX20CX2). The catalytic site is located inside a hydrophobic channel formed at the
interface of these two domains [56].
Whereas in HDACs from class I, II and IV, Zn2+ is an active participant in catalysis by
producing free acetate and deacetylated lysine, in sirtuins it does not participate in reaction.
However, the metal is essential for structural integrity, as was elucidated by the reversible
loss of activity in a P. falciparum sirtuin where the zinc ion was removed [57]. Interestingly,
an exception to the conservation of the CX2CX20CX2 motif is found on some sirtuins of
Trypanosomatids, where one of the cysteines is not present [58]. However, deacetylase
activity does not seem to be affected [59]. The molecular mechanism of deacetylation is still
not completely elucidated, but it is generally accepted that the first step in the reaction
involves the nucleophilic addition of the acetyl oxygen to nicotinamide ribose by a mecha-
nism of SN2 substitution to produce O-alkylamine intermediate and nicotinamide. Then the
acetyl group is transferred to ADP-ribose to form O-acetyl-ADP-ribose and deacetylated
lysine [60].
The founding member of the sirtuin family is Sir2 from the budding yeast and was initially
identified as part of a protein complex necessary to silence the expression of the mating-type-
loci [61, 62]. Subsequently, it was also implicated in transcriptional silencing at telomere
proximal sites [63] and ribosomal repeats at the ribosomal DNA (rDNA) locus [64–66]. Sir2
can be associated in distinct protein complexes that vary according to target site. For instance,
at telomeres and the mating-type-loci, Sir2 forms a complex with two other homologs, Sir3 and
Sir4 [63], while at rDNA locus Sir2 associates with Net1 and Cdc14 to form the regulator of
nucleolar silencing and telophase exit—RENT complex [67, 68]. Yeast cells lacking Sir2 present
a reduced lifespan that has been correlated with the accumulation of extrachromosomal ribo-
somal DNA circles originating from illegitimate recombination that are toxic to the cell and
have been associated with aging [66, 69, 70].
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In mammals, the nuclear SIRT1 is the most extensively studied member among the sirtuin
family. The TATA box binding protein-associated factor RNA polymerase I subunit B (TAFI68)
was the first substrate to be identified for SIRT1 in mouse cells. It is a transcription factor
necessary for regulating the RNA polymerase I transcriptional complex, where it was shown
that deacetylation inhibits transcriptional initiation in vitro [71]. Studies on p53, a non-histone
substrate, demonstrated that acetylation activates the DNA-binding activity and target gene
expression, also increasing its stability [72]. Consistent with this proposed SIRT1 inhibition of
p53 function, SIRT1 knockout mice exhibit p53 hyper-acetylation and increased radiation-
induced apoptosis, suggesting that SIRT1 can facilitate tumor growth by antagonism of p53
[73]. Still, the fact that SIRT1 can be found either overexpressed or underexpressed in different
tumor types, and the finding that it can also function as a tumor suppressor [74] has hindered
the clarification of its role in tumorigenesis. SIRT1 also plays an important role in metabolism,
and its relation with caloric restriction and life-span extension has received much attention
(reviewed in [75–77]). The beneficial effects of caloric restriction have been focused on the
insulin-like growth factor-1 (IGF-1) and the target of rapamycin (TOR) pathways [78, 79], but
increasing evidence suggest a role of SIRT1 in caloric restriction in mammals as well. For
instance, SIRT1 expression was found to be elevated in models of caloric restriction, like fasting
mice, low calorie diet in rat, or humans on a 25% caloric restriction diet [80–82]. On the other
hand, mice lacking SIRT1 lost the life-span extension benefits of a 40% reduced calorie diet
[83]. Despite many studies, the exact molecular mechanisms of SIRT1 in caloric restriction are
still to be unraveled.
In vitro studies attribute a role to human SIRT2 in cell cycle regulation through the
deacetylation of both tubulin and histone H4 [32, 84, 85]. In particular, it has been found that
SIRT2 overexpressing cells were significantly delayed in cell cycle progression through mitosis
[86]. Some links with age-related diseases have been described for SIRT2, such has neurode-
generative diseases [87–89], and different kinds of cancer. Mice lacking SIRT2 are prone to the
appearance of tumors, an effect believed to be mediated by SIRT2 negative regulation of the
anaphase-promoting complex [90]. It was demonstrated that SIRT2 expression is reduced in
human gliomas, some of the most frequent malignant tumors in the brain [32, 91].
SIRT3 is the major mitochondrial deacetylase and studies with double knockout mice have
revealed high levels of acetylation in protein targets [92, 93]. In addition, it was observed that
these mice have impaired production of ATP [92]. When fasting or fed with a high-fat diet, the
mice display atypical phenotypes that include cold intolerance and decreased ketone body
formation [94, 95]. This strengthened the link with thermogenesis that had been previously
demonstrated [96, 97]. In fact, SIRT3 expression is induced in mice in both white and brown
adipose tissue upon caloric restriction and exposure of brown adipose tissue to cold tempera-
tures [98]. In addition, SIRT3 also has a role in the deacetylation and activation of fatty acid
β-oxidation, amino acid metabolism, electron transport chain and antioxidant defenses [99, 100].
SIRT4 was originally thought to be an unusual sirtuin due to the lack of deacetylase activity
[101]. However, it was shown to ADP-ribosylate and down-regulate glutamate dehydrogenase
production of ATP and has been implicated in insulin regulation of β-cells [48, 101]. Moreover,
SIRT4 has recently been attributed a tumor suppressive function due to its involvement in
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DNA damage protection mediated by inhibition of mitochondrial glutamine metabolism,
suggesting it might have therapeutic potential for treating glutamine-dependent cancers
[102]. This mechanism is inhibited by mammalian target of rapamycin complex 1 (mTORC1)
pathway [103]. SIRT4 also coordinates the balance between lipid synthesis and their catabo-
lism by repressing malonyl-CoA decarboxylase, proving that it has, in fact, deacetylase
activity [49].
SIRT5 is a NAD+-dependent protein lysine demalonylase and desuccinylase [104] and also has
a deglutarylase activity [105]. It has a deacetylase activity [30], but has preference for acyl-
carboxyl negatively charged groups [104, 105]. Some of its functions are related to glycolysis
modulation [55]. The succinylome of mammalian cells has revealed many points of succin-
ylation that are possible targets of SIRT5, mostly concentrated on mitochondrial metabolism
[54]. SIRT5 also promotes urea cycle function via the regulation of carbamoyl-phosphate
synthase [30, 35], and purine metabolism via urate oxidase [106]. Although a global protein
hypersuccinylation and elevated serum ammonia during fasting were observed in SIRT5
knockout mouse model, the enzyme deficiency did not lead to any major metabolic abnormal-
ities under either low or high fat diet conditions. These observations suggest that SIRT5 is
likely dispensable for metabolic homeostasis under the basal conditions. It remains to be
evaluated the role of SIRT5 in extreme conditions [107].
While most mammalian sirtuins have been implicated with metabolism, SIRT6 seems to be the
only one with a direct link supporting a defined role in mammalian aging [108]. In fact, mice
lacking SIRT6 gene develop a progeroid-like symptom with loss of subcutaneous fat, curved
spine and lymphopenia. They develop normally for 2 weeks after birth, but then suffer from
acute degeneration processes, ending up dying at 1 month of age [109]. At first considered to
not possess deacetylase activity, but solely an ADP-ribosyltransferase activity [110], it was later
found that SIRT6 removes both acetyl and long chain acyl groups from target molecules
[53, 111]. It is localized in the nucleus, associated with chromatin, where it promotes the
specific NAD+-dependent deacetylation of H3K9 and H3K56 [111–113]. SIRT6 is involved in
genome protection by assuring correct telomere maintenance [111, 112], as well as DNA repair
by double-strand break repair machinery [114, 115]. Like other sirtuins it also has a role in
metabolism by influencing both glycolysis and gluconeogenesis [116–118] and lipid metabo-
lism, by regulating triglyceride synthesis [108, 119]. Conditions like inflammation, heart dis-
ease and cancer all seem to be linked with SIRT6 function [120].
SIRT7 is the least studied sirtuin of all the mammalian sirtuins, but recent findings have
established new functions and roles for this protein. It is a nucleolar sirtuin [121] and its
localization is associated with the main process happening at this sub-nuclear structure,
namely rDNA transcription [122]. SIRT7 does not possess a very strong deacetylate activity
toward common synthetic and natural peptides [121], which is in agreement with the fact that
SIRT7 depletion in mice did not change the global acetylation levels of either nucleus or
nucleolus proteome [123], indicating that SIRT7 deacetylase activity is specific to a limited set
of proteins. One example is specific deacetylation of H3K18 [31, 124] that underlies its role in
chromatin remodeling. Also, SIRT7 has been found to be closely associated with B-WICH
complex, a chromatin-remodeling complex [125]. It also has a role in protein synthesis [123, 126]
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and contributes to cell survival, namely by protecting against genomic insult [127, 128], hypoxia
[129] and low glucose induced stress [130]. All the functions described characterize SIRT7 as a
pro-survival protein. Indeed, it is currently considered to be an oncogene in all the cancer types
studied so far [126, 131, 132].
3. Parasitic sirtuins
Various genome-sequencing projects demonstrated the presence of genes coding for sirtuins in
most protozoan parasites of medical importance. An interesting finding was that depending
on the protozoan parasite species the number of sirtuins varied (Table 1).
Table 1. Sirtuin genes identified in genome-sequencing programs for parasitic protozoa.
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Plasmodium spp. have been shown to contain two sirtuin orthologues, called Sir2A and Sir2B.
Sir2A is the most extensively studied homolog, mainly located at the nucleus [133] although it
can also shuttle to cytoplasm after posttranslational SUMOylation [134]. Sir2A has been char-
acterized as a mediator of transcriptional silencing at the telomeric regions of chromosomes
[133, 135]. The telomeres of P. falciparum are rich in gene families involved in antigenic varia-
tion such as the var. family of genes. These genes are responsible for the expression of parasite-
derived P. falciparum erythrocyte membrane protein, PfEMP1, responsible for immune evasion
in humans [136]. The family of var. genes is tightly regulated by sirtuins, with the expression of
its members being mutually exclusive [137, 138]. The switch of active var. is controlled exclu-
sively at the epigenetic level [137, 139].
PfSir2B is a larger homolog with a molecular weight more than four times the size of Sir2A and
is involved in the transcriptional silencing of a complementary subset of var. genes with
distinct promoter types [140].
Sirtuins from Leishmania spp. parasites were among the first to be identified in Trypanosomatids,
when a complementary DNA (cDNA) isolated and sequenced from Leishmania major showed a
high homology with yeast Sir2 [141]. Antibodies raised against this LmSir2 later showed to be
reactive against different life cycle stages of L. major, but also to Leishmania amazonensis and even
to the serum of a patient infected with Leishmania infantum [142]. Furthermore, the protein was
found to be among the secreted material of L. major [142].
Overexpression of the Sir2 protein in L. infantum, sharing 93% homology to the L. major
protein, led to an increased survival of amastigotes under axenic conditions [143]. Also, when
the overexpression was performed in mammalian fibroblasts, host cells became more permis-
sive to infection by Leishmania infection in comparison with wild type cells, hinting at a
modulation of host cell by the parasite [144]. Genetic knockouts in L. infantum of the Sir2
related protein 1 (Sir2rp1) gene also highlighted the importance of this protein in the parasite.
While single knockouts were readily obtainable, double deletion of the alleles was only possi-
ble after the rescue by an ectopical copy of the gene, suggesting an essential role for parasite
survival [145]. When single-knockouts of L. infantum Sir2rp1 were used to infect a macrophage
cell line, in vitro, it was noted that although they had the same invasive capacity than wild-type
parasites, they showed a hindered replication rate leading to diminished infections over-time.
Furthermore, the mutant parasite also failed to establish an infection in an in vivomouse model
of Leishmaniasis [145]. Cellular and biochemical studies later established LiSir2rp1 has NAD+-
dependent deacetylase with ADP-ribosylation activity that co-localized to the cytoskeleton
and potentially interacted with tubulin as well as with HSP83, an orthologue of mammalian
HSP90 [146, 147]. The association with cytoskeleton is a characteristic feature of both SIRT2
and HDAC6 in mammalian cells [32, 148]. In addition, an orthologous from L. amazonensis,
LaSir2rp1 was found to be a glycosylated protein, but whether this is the case for other species
remains to be seen [149]. Although the Sir2 related protein 1 has received much attention, no
studies have been made for the other two proteins codified by the Leishmania species; Sir2
related protein 2 and Sir2 related protein 3.
Sir2rp1 from L. donovani has also been implicated in the resistance of amphotericin B, a
reference drug in the treatment of visceral Leishmaniasis. When clinical isolates were targeted
for gene knockout of the protein, parasites showed a lower level of multi-drug resistant
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transporter MDR1, lower drug efflux, increased ROS production and increased sensitivity to
amphotericin B [150]. On the contrary, overexpression led to a resistant phenotype, thereby
suggesting Sir2 as a new resistant marker for visceral Leishmaniasis [150]. Comparative
transcriptomic analysis also implicates Sir2 in resistance to miltefosine, another drug used to
treat the disease [151]. In addition to its potential as a novel drug target, Sir2rp1 from Leish-
mania spp. has also been suggested as a vaccine [152, 153].
Recently, LiSir2rp2 and LiSir2rp3, the others Leishmania sirtuins, were characterized as mito-
chondrial proteins, and while LiSir2rp3 was demonstrated to not be essential (Table 1),
attempts to generate LiSir2rp2 knockout cells failed. LiSir2rp2 was implicated in parasite
proliferation depending on NAD+ availability [154].
Trypanosoma brucei, like Leishmania spp., has 3 sirtuins annotated in its genome (Table 1). The first
enzyme to be characterized in the parasite was TbSir2rp1 [155]. The enzyme is localized mainly in
the nucleus in association with chromosomes. The protein was shown to possess both deacetylase
activity toward endogenous histones while being also able to ADP-ribosylate calf thymus histones
and, to a lesser extent, bovine serum albumin (BSA). Up to that time, no ADP-ribosylation had
been detected in common members of the sirtuin family like yeast Sir2 or HST2, hence TbSir2rp1
was one of the first enzymes to exhibit this dual activity [156–159]. Furthermore, mutation of a
catalytic histidine essential for deacetylase activity also affected ADP-ribosylation activity,
suggesting that the two activities were occurring simultaneously. Because of the increased or
decreased resistance to DNA damage caused by the alkylating drug methyl methanesulfonate
(MMS) in overexpressing or RNAi-induced knockdown T. brucei cell lines, respectively, TbSir2rp1
was also considered to have a role in DNA repair in this organism [155].
A later study performed with bloodstream forms (as opposed to insect stage forms in the
previous works) characterized TbSir2rp1 and also the other two sirtuins, TbSir2rp2 and
TbSir2rp3 that both with mitochondrial localization [160]. TbSir2rp1 was found in the nucleus,
but when overexpressed to high levels in T. brucei cells, it localizes to the cytoplasm, with toxic
effects to the parasite [160]. Besides, gene knockouts for the three proteins caused no growth in
parasites maintained in standard conditions [160]. TbSir2rp1 mutants, however, did show an
increased sensitivity to MMS damage, confirming the previous results performed with RNA
interference (RNAi). The particular localization of TbSir2rp1 led to the investigation of Sir2
mediated telomere gene silencing like the one that occurs in yeast and Plasmodium spp., as
discussed earlier [161, 162]. Although TbSir2rp1 was found to have a role in telomere DNA
repair and telomere silence, it was not required for antigenic variation [160] as described for
Plasmodium Sir2 [133, 135].
TbSir2rp1 has also been studied as a model sirtuin, with both deacetylase and ADP-
ribosylation activity. Biochemical experiments revealed that ADP-ribosylation is 5-fold less
active than the deacetylation reaction, and occurs only in the presence of an acetylated
substrate by two distinct biochemical mechanisms [163]. Another research group demon-
strated that ADP-ribosylation can also occur in arginine, independent of the presence of an
acetylated substrate, as supported by mass spectrometry and molecular dynamics simula-
tions [164].
Additional information about parasitic sirtuins can be found in a recent reviewbyHailu et al. [165].
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4. Trypanosoma cruzi sirtuins
Although the draft of the T. cruzi genome has been published a decade ago [19], it was not until
recently that the first experimental studies involving the sirtuins of this parasite have been
published. Unlike Leishmania spp. and T. brucei that possess three Sir2-like proteins, T. cruzi
only has two coding sequences annotated in its genome, TcSir2rp1 and TcSir2rp3 (Table 1).
One study employing parasites overexpressing TcSir2rp1 and TcSir2rp3 by a tetracycline
inducible vector characterized some of the features of both proteins [58]. Localization studies
employing both wild type parasites and polyclonal sera raised against both proteins, as well as
localization of tagged copies in the overexpression mutants with monoclonal antibodies,
attributed a cytoplasmic localization to TcSir2rp1 and a mitochondrial to TcSir2rp3 [58]. Both
of the proteins’ levels are regulated throughout the life cycle of the parasite, with a significant
decrease in both at the trypomastigote stage [58]. Overexpression of TcSir2rp1 was responsible
for higher metacyclogenesis and higher infectivity of Vero cells. Since metacyclogenesis occurs
under nutrient deprivation, it is hypothesized that TcSir2rp1 may function like sirtuins from
other organisms that respond to starvation [101, 166, 167]. On the other hand, overexpression
of TcSir2rp3 led to a decrease in epimastigote replication time, lower infectivity in Vero cells,
increased amastigote replication and normal metacyclogenesis [58]. Due to the oxidizing
environment in which amastigotes replicate, it has been suggested that TcSir2rp3 performs
protecting functions against oxidative stress like SIRT3 [36]. Both of the overexpressing cell
lines reduced the levels of acetylation for particular proteins, as well as protected against the
effect of specific sirtuin inhibitors [58].
Moretti and colleagues also independently characterized both of the sirtuins in a simultaneous
study [59]. In their study, they show that salermide, a sirtuin inhibitor analogue of sirtinol found
to be a strong anticancer molecule, is active against both in vitro cultures of epimastigotes, and
against an in vivomodel of infection by T. cruzi, albeit at moderate levels [59, 168]. Salermide was
also found to be a strong inhibitor of TcSir2rp3 recombinant protein [59]. The authors report the
same localization for both proteins, as well as the interference in epimastigote growth, metacyc-
logenesis, infectivity of host cells and amastigote replication in lines overexpressing the sirtuins.
Differently from Ritagliati work [58], in their studies, the overexpression of the cytosolic
TcSir2rp1 caused a decreased in the epimastigotes proliferation while TcSir2pr3 increased the
growth rate. These differences might be due to the amount of overexpression achieved and
parasite strains used [59].
5. Potential of Trypanosoma cruzi sirtuins as targets for infection control
A strategy that has been traditionally employed in Chagas disease drug discovery is the target-
based approach. One such molecular target that has gained increasing interest as a potential
drug targets against parasitic diseases is that of sirtuins [169, 170]. The hypothesis arose by
the time that it was demonstrated that sirtuins are life-span regulators in organisms like yeast,
flies and worms [70, 171, 172]. Therefore, many groups promptly investigated whether sirtuin
Chagas Disease - Basic Investigations and Challenges206
orthologues present in parasites could have important functions that could be exploited for
novel therapeutic applications.
One important aspect for the viability of targeting sirtuins in parasites is the homology between the
protein of interest andotherproteinspresent in thehost organisms.Although sirtuins are conserved
through evolution [33], significant difference at the sequence level can be found between Trypano-
somatid and human homologs. For instance, T. cruzi Sir2rp1 shares only 33% identity with mam-
malian SIRT2, its closest homolog (Multi-way protein alignment, BLOSUM62) [173].
Another argument that has led to the consideration of T. cruzi sirtuins as a drug target is that
this family of proteins is considered to possess structural properties adequate to inhibition by
small-molecule compounds. In particular, the catalytic site is located inside a hydrophobic
channel formed at the interface between the two constituting domains, the Rossman fold
containing the NAD+ binding domain and the Zn2+ ion binding domain [56]. Catalytic pockets
buried inside the protein are considered an essential feature for target druggability [174].
One last fact that prompted the evaluation of TcSir2rp1 as a drug target was the previous evidence
that a class of experimental compounds preferentially inhibited LiSir2rp1 over the human homo-
log SIRT1 [175]. The possibility to synthetize selective sirtuin inhibitors has been successfully
achieved for human homologs, based upon structural knowledge of the catalytic site as has been
demonstrated for human SIRT2 [176, 177].
Enzymatic inhibition by small molecule compounds is an essential step in the druggability
assessment of novel therapeutic targets [174]. Biochemical studies performed by our research
groups evaluated the effect of nicotinamide, a classic non-competitive inhibitor of sirtuins in
TcSir2rp1 and TcSir2rp3 (to be published). TcSir2rp1 was shown to be inhibited by nicotinamide,
albeit at a relatively high IC50 when compared with other sirtuins (4-fold higher for hSIRT1 and
11-fold higher for LiSir2rp1) [175]. Different nicotinamide sensitivities are found among distinct
sirtuins, and may explain the differences described [177]. Nicotinamide inhibits deacetylation by
binding to a conserved C pocket present in sirtuins that participates in NAD+ binding and
catalysis, where it promotes a base-exchange reaction at the expense of deacetylation [178]. A
hypothesis for the high IC50 for nicotinamide in TcSir2rp1 could be related with structural
characteristics of this conserved C pocket. Structural determination of TcSir2rp1 by X-ray crys-
tallography currently ongoing in our group will certainly highlight these differences. Contrary to
previous studies [179], we could not observe any antiparasitic activity of nicotinamide against T.
cruzi amastigotes for up to a concentration of 2 mM. Several studies report the activity of
nicotinamide against parasitic protozoa [180–182], but to our knowledge, none clearly estab-
lishes a relation between antiparasitic activity and sirtuin inhibition.
Other biochemical functions and protein interactions have been attributed to Sir2rp1 in related
Trypanosomatids, and future experiments should shed light whether it applies to TcSir2rp1.
One of the biochemical functions that has been characterized for both TbSir2rp1 and LiSir2rp1
is ADP-ribosylation. Both orthologous showed to ADP-ribosylate calf thymus histones and
BSA [155, 183]. Later studies involving TbSir2rp1 demonstrated that this biochemical function
is dependent upon acetylated histones, is coupled to the deacetylase activity of the sirtuin, but
occurs at a much lower rate than the latter [163]. In fact, even though ADP-ribosylation has
clear functions in both physiological and pathogenic situations when catalyzed by other
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ADP-ribosyltransferases [183, 184], the reaction catalyzed by sirtuins is currently challenged to
be an unspecific side-reaction [159].
Like the human SIRT2, L. infantum Sir2rp1 was also found to be associated with tubulin [146], the
major component of Trypanosomatids cytoskeleton formed by an array of subpellicular micro-
tubules that span the whole cell of the parasite [185]. SIRT2 is a tubulin deacetylase that displays
a higher affinity for tubulin than for histones [32], and has been found to be linked to regulation
of mitotic progression [86], chromatin condensation [186] and cell migration [187]. TcSir2rp1
overexpression in T. cruzi was found to increase the deacetylation level of endogenous tubulin
[58]. It is interesting to note that Sir2rp1 from T. cruzi is a cytoplasmic protein like LiSir2rp1 and
not nuclear like TbSir2rp1. Since T. cruzi shares some characteristics with L. infantum like the
amastigote intracellular stage, it should not be ruled out that Sir2rp1 may have functions in the
cytoskeleton remodeling necessary for stage differentiation. Several proteins, sirtuins included,
have demonstrated the ability to shuttle from the nucleus to the cytoplasm and vice-versa
[188, 189]. SIRT2, the closest sirtuin homolog of mammalian cells, is actively exported to the
cytoplasm during interphase, but is accumulated in the nucleus from prophase until cytokinesis
where it co-localizes with important mitotic structures like centrosomes and the mitotic spindle
[190]. Curiously, analysis of TcSir2rp1 by Wregex and cNLS Mapper, bio-computational tools
that identify nuclear export signals (NES) and nuclear localization signals (NLS), respectively,
indicate the presence of non-canonical NES/NLS in the sequence of this sirtuin [191, 192].
Whether TcSir2rp1 does shuttle to the nucleus during specific phases of T. cruzi life cycle, for
instance to repair DNA damage like the T. brucei orthologue, remains to be reported.
The mitochondrial TcSir2rp3 was found less expressed in T. cruzi forms proliferating in mam-
malian cells. Its expression increased when the parasite transformed in trypomastigotes [59].
The fact that cells overexpressing only the active form, but not the inactive form of TcSir2rp3
showed an increased intracellular growth and failed to transform in to extracellular
trypomastigotes [59], suggested that it could also be a drug target to control the infection,
although further experiments to generate knockout cell lines need to be performed. We
recently identified several compounds that prevented intracellular growth of T. cruzi some of
them inhibiting specifically TcSir2rp1 or TcSir2rp3 which might indicate the requirement of
both enzymes for the parasite (to be published).
6. Naphtalimide derivatives as potential drugs for Chagas disease control
Naphthalimides are a class of compounds that have generated intense interest as active molecules
with potential to treat a range of conditions [193]. A naphthalene ring linked to an imide group that
forms a third heterocycle composes the basic chemical scaffold of the naphthalimide derivatives.
This moiety has a planar nature and is considered to be responsible for the pharmacological
activities attributed to compounds derived from this structure, that can be as distinct as anticancer,
antibacterial, antiprotozoal, antiviral, analgesic, and anesthetic [193]. Their potential as anticancer
compounds has received particular attention,mostly because of theirDNA intercalating properties
and also to their reported activity as topoisomerase inhibitors [194–196]. Compounds like amona-
fide and bisnafide have been proposed as anticancer agents and have inclusively reached clinical
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trials in the past [197, 198]. Elinafide is another derivativewith two naphthalimidemoieties that has
been evaluated in preclinical studies and demonstrated potential against various mouse xenograft
models [199]. This last compoundwas in the origin of the synthesis of the first BNIPs that differed in
the alkyl chain linking the naphthalimide and amine group, i.e. a propyl instead of an ethyl chain
[200]. These derivatives showedpotential activity against breast cancerMCF-7 cell line and actively
boundDNAasdemonstrated by thermal denaturationmeasurements, ethidiumbromidedisplace-
ment andDNAgelmobility [200]. Later derivatives that varied in the length of the chain linking the
two amines of bisnaphthalimidopropyl groups were also evaluated against cancer cell lines and
promastigotes of the parasite L. infantum [201]. While screening for enzymatic inhibitors of the
recently characterized LiSir2rp1, BNIPs were identified as inhibitors of its deacetylase activity
[175]. Furthermore, they were active against intracellular amastigotes, the clinically relevant stage
of the parasite present in humans, at concentrations in the singlemicromolar range [175].
Our groups’ previous results demonstrating activity toward L. infantum led to the testing of
BNIPs as inhibitors of the related Trypanosomatid T. brucei and its Sir2rp1 orthologue, TbSir2rp1
[202]. BNIPs revealed to be very potent inhibitors of in vitro parasite growth, with one of the
compounds, BNIPDabut (Figure 1) with an EC50 in the range of the reference drug pentamidine.
However, when tested against the TbSir2rp1 recombinant enzyme, BNIPDabut had an IC50more
than 104 times superior to the EC50 against the whole cell parasite, indicating that Sir2rp1
inhibition is probably not a major mechanism of action for the compound. Whether BNIPDabut
inhibits other T. brucei sirtuin enzymes remains to be elucidated. It should be noted that RNAi
and gene knockout experiments of the three sirtuins did not led to a deleterious effect, and unlike
LiSir2rp1, there is no indication of that these proteins may be essential [155, 160]. The optimal
in vitro properties of BNIPDabut led to the testing with an in vivo model of trypanosomiasis by
bioluminescence imaging. Although BNIPDabut maintained a strong trypanocidal activity
in vivo, as assessed by the decrease in bioluminescent signals to levels similar to those of the
reference drug control pentamidine, it was not sufficient for infection clearance, as animals’
parasitaemia relapsed shortly after treatment interruption. Nevertheless, BNIPDabut should
constitute a scaffold for further consideration in HATdrug discovery [202].
In a different study, BNIP derivatives were also tested against TcSir2rp1 and in vitro cultures of T.
cruzi amastigotes (unpublished results). BNIPs demonstrated to inhibit the deacetylase activity of
this enzyme, with BNIPSpd (Figure 1) as the most potent compound, showing a dose-dependent
effect on inhibition. BNIPSpd also proved to be active and selective against amastigotes of T. cruzi
in a high content screening (HCS) assay – an assay that takes advantage of computer-assisted
image processing of hundreds of microscopic images originating in automated microscopes able
to simultaneously capture multiple conditions or drug compounds. In this work, a new set of
derivatives was also synthetized in order to improve both solubility and binding to cellular
targets, mostly by including cyclic structures and heteroatoms in the carbon chain linking the
two naphthalimide groups. Themost active compoundswere BCNIPP, also a TcSir2rp1 inhibitor,
and trans BNIP-1,4-Dacyhex, a derivative of BNIPDabut that weakly inhibited the enzyme. In
turn, BNIPDabut had some inhibitory activity on T. cruzi amastigotes, with low selectivity, but
also did not inhibit TcSir2rp1 at 10 μM. The activity of BNIPSpd in a mice model of Chagas
disease using bioluminescent parasites was also determined and found to be absent at the doses
tested. An explanation might be the poor pharmacokinetic profile of the compounds, which fails
to ever achieve at least the in vitro IC50 against T. cruzi amastigotes.
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Altogether, our data indicate that BNIP derivatives may not be acting only by a mechanism of
Sir2rp1 inhibition, with other targets contributing to the activity detected. BNIPs were origi-
nally designed and developed as anti-cancer agents [203, 204] through DNA intercalation. This
property might explain some of the cytotoxic effects verified against host cells, but may also be
an important mechanism of activity toward the parasite, especially since trypanosomes are
highly susceptible to intercalating agents [205].
Confirmation of themechanism of action can be undertaken by appropriate target deconvolution
experiments [206]. The most common type of such experiments are biochemical methods that
employ some variation of biochemical affinity purification, where the compounds are immo-
bilized in a column, and allowed to interact with protein extracts, preferably previously fraction-
ated. After stringent washing steps, the bound proteins are eluted and identified. Such strategy
has been employed in the identification of small molecule activators of cryptochrome of mam-
malian cells [207]. A disadvantage is that there is a bias toward high affinity ligands, and when
the target is relatively less abundant or has less affinity, important targets may not be detected.
Furthermore, the washing steps may eliminate protein complexes that may be important for
appropriate drug activity.
Genetic methods can also be valuable for target deconvolution. Gene knockouts and RNAi
screens can be used to try to phenotype a compound’s effect [208]. Furthermore, if the mutant
is hypersensitive to the compound in question, the evidence that the protein could be the target
for the compounds would be strengthened. The validation of trypanothione synthetase and
N-myristoyltransferase as drug targets against trypanosomes are examples where the differen-
tial sensitivity of an inhibitor in wild type, overexpression, and knockout mutants is clearly
illustrated [209, 210]. An additional genetic strategy is based on the generation of resistant cell
lines by culturing the parasites in increasing sub-lethal drug concentrations that are posteriorly
sequenced to find mutated genes related to the mechanism of action for the compound [208].
Genetic methods have recently been employed in the search of the mechanism of action of
oxaboroles [211], a class of compounds in development for HAT, but also active against T. cruzi
[212, 213].
Chemical genomics can also be applied to the discovery of novel drug targets, as exemplified
by the recent characterization of cytochrome b from T. cruzi. This enzyme was demonstrated to
be selectively targeted in relation to the human homolog by a hit compound coming from a
phenotypic screening [214].
7. Perspective
Here we highlighted the potential of sirtuins, particularly in the T. cruzi as possible targets of
drug development for Chagas disease for the following reasons:
1. The parasite contains only two sirtuins, instead of three present in Leishmania spp. and T.
brucei species, and seven in the human host, which facilitates a more precise design and
avoid redundant effects.
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2. Several experiments demonstrate the requirement of these enzymes for growth and sur-
vival, particularly in intracellular forms of the parasite, which are clinically relevant.
3. There are several compounds already designed to be selective sirtuin inhibitors that could
be modified to provide increased specificity and selectivity to the parasite enzyme. Some
of these compounds have already defined druggability and specific derivatives can be
repurposed more easily.
4. Both sirtuins were produced to perform enzymatic screenings and crystals of TcSir2rp1
have been obtained to be the basis of further medicinal chemistry.
Finally, several lead compounds were identified for T. cruzi sirtuin, which can provide the basis
for future development. It is also important to note that these possible inhibitors could act
synergistically with drugs already in use for treatment, as a novel combinational therapy,
opening new avenues to eliminate Chagas disease.
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